ID: ALA398175

Max Phase: Preclinical

Molecular Formula: C27H28Cl2N4O

Molecular Weight: 495.45

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1cccc(-c2ccc(C(=O)NC/C=C/CN3CCN(c4cccc(Cl)c4Cl)CC3)cc2)n1

Standard InChI:  InChI=1S/C27H28Cl2N4O/c1-20-6-4-8-24(31-20)21-10-12-22(13-11-21)27(34)30-14-2-3-15-32-16-18-33(19-17-32)25-9-5-7-23(28)26(25)29/h2-13H,14-19H2,1H3,(H,30,34)/b3-2+

Standard InChI Key:  IEANVAFYLZJSPC-NSCUHMNNSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 495.45

Molecular Weight (Monoisotopic): 494.1640

AlogP: 5.47

#Rotatable Bonds: 7

Polar Surface Area: 48.47

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 6.41

CX LogP: 5.49

CX LogD: 5.44

Aromatic Rings: 3

Heavy Atoms: 34

QED Weighted: 0.44

Np Likeness Score: -1.39

References

1. Grundt P, Prevatt KM, Cao J, Taylor M, Floresca CZ, Choi JK, Jenkins BG, Luedtke RR, Newman AH..  (2007)  Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents.,  50  (17): [PMID:17672446] [10.1021/jm0704200]

2.  (2014)  4-phenylpiperazine derivatives with functionalized linkers as dopamine D3 receptor selective ligands and methods of use, 

Source

Source(2):

• Scientific Literature
• BindingDB Database